Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Carcinoma, Transitional Cell 3Ureteral Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 6Sorafenib 4Filgrastim 4Carboplatin 4Thiotepa 3Radiotherapy 3Psychiatric Rehabilitation 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3sargramostim 2ixabepilone 2fludarabine 2Temozolomide 2Sirolimus 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gene Expression Profiling 2Etoposide 2Drug Therapy 2Counseling 2Busulfan 2Bupropion 2Blood Specimen Collection 2Biopsy 2vofatamab 1utomilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Ramucirumab × Genitourinary × Clear all
NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Completed
97 enrolled 20 charts
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡